title: Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor.
abstract: The conventional protein kinase C isoform, PKCII, is a signaling kinase activated during the hyperglycemic state and has been associated with the development of microvascular abnormalities associated with diabetes. PKCII, therefore, has been identified as a therapeutic target where inhibitors of its kinase activity are being pursued for treatment of microvascular-related diabetic complications. In this report, we describe the crystal structure of the catalytic domain of PKCbetaII complexed with an inhibitor at 2.6 A resolution. The kinase domain of PKCbetaII was cleaved and purified from full-length PKCbetaII expressed in baculovirus-infected insect cells. The overall kinase domain structure follows the classical bilobal fold and is in its fully activated conformation with three well-defined phosphorylated residues: Thr-500, Thr-641, and Ser-660. Different from the crystal structures of nonconventional PKC isoforms, the C-terminus of the PKCbetaII catalytic domain is almost fully ordered and features a novel alpha helix in the turn motif. An ATP-competitive inhibitor, 2-methyl-1H-indol-3-yl-BIM-1, was crystallized with the PKCbetaII catalytic domain as a dimer of two enzyme-inhibitor complexes. The bound inhibitor adopts a nonplanar conformation in the ATP-binding site, with the kinase domain taking on an intermediate, open conformation. This PKCbetaII-inhibitor complex represents the first structural description of any conventional PKC kinase domain. Given the pathogenic role of PKCbetaII in the development of diabetic complications, this structure can serve as a template for the rational design of inhibitors as potential therapeutic agents.
authors.affiliation: Department of Structural and Computational Biology and Design, Pfizer Global Research and Development, Pfizer La Jolla Laboratories, 10777 Science Center Drive, San Diego, California 92121, USA.
authors.forename: Neil
authors.initials: N
authors.lastname: Grodsky
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.forename: Djamal
authors.initials: D
authors.lastname: Bouzida
authors.forename: Robert
authors.initials: R
authors.lastname: Love
authors.forename: Jordan
authors.initials: J
authors.lastname: Jensen
authors.forename: Beverly
authors.initials: B
authors.lastname: Nodes
authors.forename: Jim
authors.initials: J
authors.lastname: Nonomiya
authors.forename: Stephan
authors.initials: S
authors.lastname: Grant
mesh_terms: D000595:Amino Acid Sequence; D020134:Catalytic Domain; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007700:Kinetics; D008301:Maleimides / Q000494:pharmacology*; D008958:Models, Molecular; D008969:Molecular Sequence Data; D010766:Phosphorylation; D011487:Protein Conformation; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000737:chemistry*; D064546:Protein Kinase C beta; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry; D017386:Sequence Homology, Amino Acid
chemical_list: D007211:Indoles; D008301:Maleimides; D047428:Protein Kinase Inhibitors; D011994:Recombinant Proteins; D011493:Protein Kinase C; D064546:Protein Kinase C beta; C088060:bisindolylmaleimide